Discrimination measurements for the external validation of model 2 considering preoperative PVR
| Original series | Validation series | 95% CI | ||
|---|---|---|---|---|
| Inferior | Superior | |||
| Model 2 | ||||
| Temporal sample | ||||
| Sensitivity (%) | 67.31 | 66.67 | 42.81 | 90.52 |
| Specificity (%) | 85.96 | 81.54 | 72.11 | 90.97 |
| Positive predictive value (%) | 68.63 | 45.45 | 24.65 | 66.26 |
| Negative predictive value (%) | 85.22 | 91.38 | 84.16 | 98.6 |
| Accuracy (%) | 80.12 | 78.75 | 69.79 | 87.71 |
| Geographical sample | ||||
| Sensitivity (%) | 67.31 | 58.72 | 49.47 | 67.96 |
| Specificity (%) | 85.96 | 75.17 | 70.17 | 80.18 |
| Positive predictive value (%) | 68.63 | 47.41 | 38.98 | 55.83 |
| Negative predictive value (%) | 85.22 | 82.69 | 78.09 | 87.29 |
| Accuracy (%) | 80.12 | 70.63 | 66.14 | 75.12 |
PVR, proliferative vitreoretinopathy.